News | September 02, 2021
Morpen Laboratories to transfer its medical devices business to a wholly owned subsidiary
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
The drug is also intended for the treatment of glioblastoma multiforme
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
Subscribe To Our Newsletter & Stay Updated
